| Patents for A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128) |
|---|
| 03/29/2011 | US7915219 treatment of cell damage caused by ischemia or stroke by administering to a cell or a tissue an effective amount of an isozyme specific delta PKC (protein kinase C) antagonist |
| 03/29/2011 | US7914820 Film coating for tablets and caplets |
| 03/29/2011 | US7914816 Endoparasiticidal agents for voluntary oral ingestion by animals |
| 03/29/2011 | US7914806 Medical devices having improved performance |
| 03/29/2011 | US7914793 Method for producing an antigenic substance and antibody |
| 03/29/2011 | US7914787 Provide inter alia a bi-specific antibody or antibody fragment having one arm that specifically binds a targeted tissue and one other arm that specifically binds a targetable conjugate that can be modified for use in a wide variety of diagnostic and therapeutic applications |
| 03/29/2011 | US7914784 Insulin-like growth factor I receptor (IGF-IR) specific monoclonal antibodies for diagnosis, prevention and treatment of cell proliferative disorders |
| 03/29/2011 | US7914780 Aminopeptidase A (APA) targeting peptides for the treatment of cancer |
| 03/29/2011 | US7914768 Stabiliser for radiopharmaceuticals |
| 03/29/2011 | CA2642324C Stable pharmaceutical composition of taxanes |
| 03/29/2011 | CA2466671C Microspherules containing a pleuromutilin derivative |
| 03/29/2011 | CA2452845C Dye-sulfenates for dual phototherapy |
| 03/29/2011 | CA2448083C Liquid preparations of fudosteine |
| 03/29/2011 | CA2421974C Pulmonary delivery in treating disorders of the central nervous system |
| 03/29/2011 | CA2420562C Creatine ester pronutrient compounds and formulations |
| 03/29/2011 | CA2418784C Use of compounds derived from the genus euphorbia for the treatment of carcinoma of the bladder |
| 03/29/2011 | CA2407514C Rgd (arg-gly-asp) coupled to (neuro)peptides |
| 03/29/2011 | CA2397016C Use of lipid conjugates in the treatment of disease |
| 03/29/2011 | CA2390164C Substituted 4h-chromene and analogs as activators of caspases and inducers of apoptosis and the use thereof |
| 03/29/2011 | CA2387611C Manufacture of polyglutamate-therapeutic agent conjugates |
| 03/29/2011 | CA2385455C Polydisperse double emulsion, corresponding monodisperse double emulsion and method for preparing the monodisperse emulsion |
| 03/29/2011 | CA2381992C Method of treating metabolic disorders, especially diabetes, or a disease or condition associated with diabetes |
| 03/29/2011 | CA2379508C Biphasic skin composition comprising ascorbic acid, ceramides and betaglycane |
| 03/29/2011 | CA2345276C Flt4 (vegfr-3) as a target for tumor imaging and anti-tumor therapy |
| 03/29/2011 | CA2252438C Histidine-tagged intimin and methods of using intimin to stimulate an immune response and as an antigen carrier with targeting capability |
| 03/29/2011 | CA2165573C Anti-.alpha.v-integrin monoclonal antibody |
| 03/24/2011 | WO2011035321A1 Treatment of wnt/frizzled-related diseases |
| 03/24/2011 | WO2011035279A2 Nanocarriers for imaging and therapy applications |
| 03/24/2011 | WO2011035065A1 Monoconjugated chitosans as delivery agents for small interfering nucleic acids |
| 03/24/2011 | WO2011034551A2 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
| 03/24/2011 | WO2011034513A1 The granules with improved solubility and stability |
| 03/24/2011 | WO2011034465A1 A pharmaceutical composition for peroral administration of diindolylmethane |
| 03/24/2011 | WO2011034396A2 Solid dispersion comprising a fibrate drug, and method for preparing the solid dispersion |
| 03/24/2011 | WO2011034323A2 Transdermal delivery system, method for manufacturing the same, and transdermal delivery method using the system |
| 03/24/2011 | WO2011034192A1 Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| 03/24/2011 | WO2011034105A1 Modified erythropoietin to which water-soluble long-chain molecule is added |
| 03/24/2011 | WO2011034039A1 Eradicating agent and eradication method for helicobacter pylori |
| 03/24/2011 | WO2011033085A1 Rapidly soluble solid pharmaceutical preparations containing amphiphilic copolymers based on polyethers in combination with hydrophilic polymers |
| 03/24/2011 | WO2011033068A1 Long-acting y2 receptor agonists |
| 03/24/2011 | WO2011033019A1 Stable non-aqueous liquid pharmaceutical compositions comprising an insulin |
| 03/24/2011 | WO2011032916A1 Pellets coated with coatings containing active substances |
| 03/24/2011 | WO2011032907A1 Solid pharmaceutical preparations comprising amphiphilic copolymers on the basis of polyethers in combination with surfactants |
| 03/24/2011 | WO2011032416A1 Pharmaceutical composition containing dopamine receptor agonist |
| 03/24/2011 | WO2011032386A1 Osmotic pump controlled release tablet and preparation method thereof |
| 03/24/2011 | WO2011032318A1 Stable artesunate-amodiaquine hydrochloride complex tablet and preparation method thereof |
| 03/24/2011 | WO2011032229A1 A novel epsilon polymorphic form of inulin and compositions comprising same |
| 03/24/2011 | WO2011013130A3 Cell-targeting nanoparticles comprising polynucleotide agents and uses thereof |
| 03/24/2011 | WO2011013128A3 Vectors for delivery of neurotherapeutics to the central nervous system |
| 03/24/2011 | WO2011009539A8 ε-POLYLYSINE CONJUGATES AND USE THEREOF |
| 03/24/2011 | WO2010149980A3 Topical formulation containing a tetracycline and a method of treating skin infections using the same |
| 03/24/2011 | WO2010148007A9 Nanoparticle and polymer formulations for thyroid hormone, analogs, antagonists, and formulations and uses thereof |
| 03/24/2011 | WO2010132410A3 Solid cosmetic composition with structurant and electrolyte solution |
| 03/24/2011 | WO2010129545A3 Porous silicon drug-eluting particles |
| 03/24/2011 | WO2010128793A3 Fat soluble vitamin and a derivative thereof induced by novel cationic chitosan, a method of producing same and drug delivery system containing same |
| 03/24/2011 | WO2010122358A3 Chewable oral delivery system |
| 03/24/2011 | WO2010111178A4 Drug depots for treatment of pain and inflammation in sinus and nasal cavities or cardiac tissue |
| 03/24/2011 | WO2010099552A8 Devices, systems and methods for magnetic-assisted therapeutic agent delivery |
| 03/24/2011 | WO2009143174A3 Chemical permeation enhancers enhance nerve blockade by toxins |
| 03/24/2011 | WO2008116468A8 Mhc peptide complexes and uses thereof in infectious diseases |
| 03/24/2011 | US20110071612 Anti-angiogenic compositions and methods of use |
| 03/24/2011 | US20110071495 Shape memory embolic particles having a high packing fraction |
| 03/24/2011 | US20110071228 Insecticidal formulations with improved long-term effect on surfaces |
| 03/24/2011 | US20110071227 Rapidly wetting material containing hydrocolloid, method for the manufacture thereof and use thereof |
| 03/24/2011 | US20110071186 Organic compounds |
| 03/24/2011 | US20110071122 System for use by compounding pharmacists cists to produce hormone replacement medicine customized for each customer |
| 03/24/2011 | US20110071118 Methods of Making Compositions Comprising Lecithin Oils and NSAIDS for Protecting the Gastointestinal Tract and Providing Enhanced Therapeuitc Activity |
| 03/24/2011 | US20110070309 Pharmaceutical formulation comprising a water-insoluble active agent |
| 03/24/2011 | US20110070288 Composite layered hemostasis device |
| 03/24/2011 | US20110070276 Bioactive keratin peptides |
| 03/24/2011 | US20110070231 Stable liquid pharmaceutical formulation of igg antibodies |
| 03/24/2011 | US20110070224 Methods compositions and devices utilizing stinging cells/capsules for delivering a therapeutic or a cosmetic agent into a tissue |
| 03/24/2011 | US20110070213 Dermal compositions containing coenzyme q as the active ingredient |
| 03/24/2011 | US20110070198 Plant-based biocidal materials and systems |
| 03/24/2011 | US20110070188 Bab triblock polymers having improved release characteristics |
| 03/24/2011 | US20110070176 Method for the treatment of acne using compositions comprising 0.3% by weight of 6-[3-(1-adamantyl)-4-methoxyphenyl]-2-naphthoic acid |
| 03/24/2011 | US20110070173 Oil-in-Water Type Emulsion Cosmetic Composition |
| 03/24/2011 | US20110070172 Rebaudioside C and Its Stereoisomers as Natural Product Sweetness Enhancers |
| 03/24/2011 | US20110070165 Multivalent constructs for therapeutic and diagnostic applications |
| 03/24/2011 | US20110070155 Anti-CD74 Immunoconjugates and Methods |
| 03/24/2011 | CA2838352A1 Novel heparin entities and methods of use |
| 03/24/2011 | CA2812158A1 Bisphosphonate-prostatic acid phosphatase inhibitor conjugates to treat prostate cancer bone metastasis |
| 03/24/2011 | CA2774645A1 Pharmaceutical composition for peroral administration of 3,3'-diindolylmethane |
| 03/24/2011 | CA2774526A1 Bab triblock polymers having improved release characteristics |
| 03/24/2011 | CA2774525A1 Reconstitutable reverse thermal gelling polymers |
| 03/24/2011 | CA2774210A1 Oral solid dosage form containing nanoparticles and process of formulating the same using fish gelatin |
| 03/24/2011 | CA2774168A1 Pharmaceutical formulations comprising 9-cis-retinyl esters in a lipid vehicle |
| 03/24/2011 | CA2774053A1 Stable co-formulation of hyaluronidase and immunoglobulin, and methods of use thereof |
| 03/24/2011 | CA2774015A1 Treatment of cancer |
| 03/24/2011 | CA2773597A1 Latanoprost-containing aqueous eye drops and method for inhibiting adsorption of latanoprost to resin |
| 03/24/2011 | CA2773596A1 Modified erythropoietin to which water-soluble long-chain molecule is added |
| 03/24/2011 | CA2773592A1 Method and composition for treating alzheimer-type dementia |
| 03/24/2011 | CA2771336A1 Synergistic anti-cd47 therapy for hematologic cancers |
| 03/24/2011 | CA2715242A1 Crosslinked polysiloxanes, a process for their preparation and use of the crosslinked polysiloxanes in emulsifier systems for water-in-oil emulsions |
| 03/23/2011 | EP2298806A1 Antibodies that bind cell-associated CA 125/0722P and methods of use thereof |
| 03/23/2011 | EP2298792A2 Peptides targeted to protein kinase C isoforms and uses thereof |
| 03/23/2011 | EP2298736A1 Hydrazine-based and carbonyl-based bifunctional crosslinking reagents |
| 03/23/2011 | EP2298728A1 Transfection reagents |
| 03/23/2011 | EP2298358A1 Methods for delivery of nucleic acids |
| 03/23/2011 | EP2298356A2 Multivalent VLA-4 antagonists comprising polymer moieties |
| 03/23/2011 | EP2298355A2 Albumin fusion proteins |